Navigation Links
diaDexus, Inc. Reports 2011 Fourth Quarter and Year-End Financial Results
Date:3/16/2012

SOUTH SAN FRANCISCO, Calif., March 15, 2012 /PRNewswire/ -- diaDexus, Inc. (OTC Bulletin Board: DDXS), a company focused on the development and commercialization of proprietary cardiovascular diagnostic products, today announced financial results for the 2011 fourth quarter and year-end.

Fourth quarter 2011

Total revenues for the 2011 fourth quarter were $4.9 million, a 48% increase over $3.3 million for the fourth quarter of 2010, representing the highest quarterly revenues in the history of the company.  Total expenses for the quarter were $5.8 million, unchanged from the fourth quarter of 2010. The company's net loss for the quarter was $1.0 million compared to a $2.1 million net loss in the fourth quarter of 2010. The decrease in net loss for the quarter was largely due to a $1.6 million increase in fourth quarter sales of the PLAC® Test for Lp-PLA(2) versus the comparable 2010 period.  Net cash used in operating activities for the fourth quarter of 2011 was $1.6 million versus $2.8 million for the same period the year prior.

Year-end 2011

Total revenues for the 12-month period ended December 31, 2011 were $16.4 million compared to  $11.8 million for 2010.  This 39% increase was due to accelerated demand for the company's PLAC® Test for Lp-PLA(2) and represents record annual revenues. Total operating expenses for 2011 were $24.2 million compared to total operating expenses of $20.4 million in 2010. The company reduced its net loss to $7.5 million for the year ended December 31, 2011, compared to a net loss of $8.4 million in 2010. Net cash used in operating activities was $6.7 million in 2011 versus $7.5 million in 2010, also primarily a result of higher revenues.

Cash and investments at December 31, 2011 were $17.2 million compared to $20.4 million at December 31, 2010.

Guidance

diaDexus maintained
'/>"/>

SOURCE diaDexus, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. diaDexus, Inc. Adds Two New Directors; Corporate Overview & 3Q Results Webcast Set for November 16, 2010
2. diaDexus, Inc. Reports 2010 Third Quarter Financial Results
3. diaDexus, Inc. Reports 2011 First Quarter Financial Results
4. diaDexus, Inc. Reports 38% Year-Over-Year Revenue Growth for 2011 Third Quarter
5. diaDexus, Inc. to Host Webcast March 15, 2012 on 2011 Fourth Quarter and Year-End Financial Results
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. Spherix Reports Second Quarter Earnings
8. Tapestry Reports Second Quarter 2007 Results
9. Callisto Reports on Second-Quarter 2007 Milestones
10. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
11. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... A new analysis and infographic released ... Hepatitis C medications could range from hundreds of millions of ... Hepatitis C receive treatment through state programs. The analysis, which ... on public programs, comes at a time when state and ... Gilead Sciences, Harvoni and Sovaldi. ...
(Date:6/30/2015)...  Inari Medical, Inc. announced today that it has ... The financing was led by members of the board ... Venture Partners.  The round also included participation by several ... pleased to complete this financing with the support of ... who joined in February 2015 as President and Chief ...
(Date:6/30/2015)... 30, 2015 Oramed Pharmaceuticals Inc. ... pharmaceutical Company focused on the development of oral drug ... been screened in the Company,s Phase IIb trial of ... will be performed under the active Investigational New Drug ... Drug Administration (FDA). The Phase IIb study ...
Breaking Medicine Technology:New Analysis Reveals High-Priced Hepatitis C Drugs Could Have Costly Impact on State 2New Analysis Reveals High-Priced Hepatitis C Drugs Could Have Costly Impact on State 3New Analysis Reveals High-Priced Hepatitis C Drugs Could Have Costly Impact on State 4Oramed Enrolls First Patient in its Phase IIb Oral Insulin Study 2Oramed Enrolls First Patient in its Phase IIb Oral Insulin Study 3
... Mass.--(BUSINESS WIRE)--Jul 9, 2007 - Pro-Pharmaceuticals,Inc. (Amex: ... updated the progress of its Phase II,clinical ... cancer patients who are unable to tolerate ... trial for first-line,treatment of biliary cancer patients. ...
... Late-breaking Phase III,clinical trial data presented today ... Haemostasis (ISTH) Congress demonstrate,that once-daily rivaroxaban achieved ... (VTE) in patients undergoing,knee replacement surgery in ... of care. Patients in the RECORD3,(REgulation of ...
Cached Medicine Technology:Pro-Pharmaceuticals Updates Progress of Clinical Trials &,Davanat 505 (b)(2) Filings 2Pro-Pharmaceuticals Updates Progress of Clinical Trials &,Davanat 505 (b)(2) Filings 3Pro-Pharmaceuticals Updates Progress of Clinical Trials &,Davanat 505 (b)(2) Filings 4Pro-Pharmaceuticals Updates Progress of Clinical Trials &,Davanat 505 (b)(2) Filings 5Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 2Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 3Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 4Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 5
(Date:6/30/2015)... FL (PRWEB) , ... June 30, 2015 , ... According ... doubled from 2007 to 2013 while heroin-related deaths more than tripled in the same ... threat (1). Novus Medical Detox Center , a leading Florida-based drug treatment facility, ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... According to ... received a $3.1 million grant to study how sensory stimuli can be used to ... emphasis on improving care for children with autism, will compare patient experience in a ...
(Date:6/30/2015)... ... June 30, 2015 , ... Lakeview Health, a drug and ... size of its medical staff to further enhance its ability to treat addiction ... practitioners and physician assistants -- now totals 17, compared to 7 in 2013, ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... pending in a federal multidistrict litigation now underway in the U.S. District Court, ... monthly Status Conference. According to the Court’s calendar, that conference has now been ...
(Date:6/30/2015)... ... 30, 2015 , ... Dr. Sammy Masri of Masri Sports Medicine &Wellness, NJ ... the diagnosis and treatment of non-surgical sports and other musculoskeletal injuries for both adults ... athletics and use exercise to stay healthy and active. Dr. Masri seeks to provide ...
Breaking Medicine News(10 mins):Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 2Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 3Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 4Health News:New Study Aims to Determine if Sensory Stimuli can Ease Dental Anxiety in Children, Notes Medical Center Dental Care 2Health News:New Study Aims to Determine if Sensory Stimuli can Ease Dental Anxiety in Children, Notes Medical Center Dental Care 3Health News:Lakeview Health, a Nationally Recognized Drug Rehabilitation Center in Florida, Doubles Size of Medical Staff 2Health News:Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference 2Health News:Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference 3Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 2Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 3Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 4Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 5
... Researchers have discovered that some women carry a genetic ... respond to ovarian stimulating hormones during fertility treatment. The ... devising personalised fertility treatments that could bypass the problem ... told the 26th annual meeting of the European Society ...
... ... based laboratory equipment repair and instrument calibration services company, has been formally approved ... lab., , ... (PRWEB) June 29, 2010 -- Beginning in 2009, the AL-TAR Quality Department ...
... Want to lose ... weight off permanently and enjoy top physical fitness levels? See what Brilliance Weight Loss has to ... (PRWEB) June 29, ... and its customer base, as it continues to gain success with showing people how to ...
... Azmacort and ... an equivalent medication. Many have chosen to write into the People,s Medicine Community to express ... Learn more about the FDA,s decision and connect with other individuals through this special report. ... Westlake Village, CA (PRWEB) ...
... By Randy Dotinga HealthDay Reporter , MONDAY, June ... who take the cholesterol-lowering drugs known as statins are a ... But don,t demand that your doctor prescribe a statin ... for you just yet. The findings aren,t firm enough ...
... immune cell known to cause chronic inflammation in autoimmune ... low back pain associated with herniated discs, according to ... finding implicates the cytokine molecule interleukin-17, and supports the ... role in disc disease, says William J. Richardson, MD, ...
Cached Medicine News:Health News:Study finds why some women are sub-fertile with a poor response to ovarian stimulating hormones 2Health News:Study finds why some women are sub-fertile with a poor response to ovarian stimulating hormones 3Health News:AL-TAR Services, Inc. Laboratory Is Now Accredited For ACLASS Standards 2Health News:Brilliance Weight Loss Takes Dieters Beyond Trendy Low Fat Diets 2Health News:Impact of Azmacort Withdrawal Brought to Light in Medicine Community 2Health News:Impact of Azmacort Withdrawal Brought to Light in Medicine Community 3Health News:Impact of Azmacort Withdrawal Brought to Light in Medicine Community 4Health News:Impact of Azmacort Withdrawal Brought to Light in Medicine Community 5Health News:Statins May Lower Rates of Prostate Cancer Recurrence 2Health News:Surprising find may yield new avenue of treatment for painful herniated discs 2
... A surgically implanted bone growth stimulator ... EBI OsteoGen surgically implanted bone growth stimulator ... of nonunions when surgery is already planned ... concern. Because the OsteoGen is totally surgically ...
... area contact between grant material and fracture ... long bones., ,Grid-Like Format of Mesh Cathode ... Bone , ,The innovative Mesh Cathode of ... area and a scaffolding effect designed to ...
... Flexible Cystoscope System using EndoSheath Technology ... for urologists in both their hospitals ... CST-2000 flexible cystoscope with the sterile, ... cystoscopy procedures, while minimizing the costs ...
... The PK Plasma-CISE™ (wire electrodes) ... single use devices that produce ... minimal thermal spread and Vapor ... superior hemostasis. The devices provide ...
Medicine Products: